Dyadic signs new dairy protein deal with European biotech firm

Go back to Dyadic signs new dairy protein deal with European biotech firm

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

August 4, 2026 7:25 AM EDT

New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategy

JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins.

The agreement further expands Dyadic's growing... More